Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection.
about
Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammationThe endocannabinoid system as an emerging target of pharmacotherapyHarm reduction--the cannabis paradoxRole of microglial m1/m2 polarization in relapse and remission of psychiatric disorders and diseasesEffect of cannabis smoking on lung function and respiratory symptoms: a structured literature reviewRole of Cannabinoids in Gastrointestinal Mucosal Defense and InflammationAttenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells.Cannabinoids as novel anti-inflammatory drugs.Modulation of gut-specific mechanisms by chronic δ(9)-tetrahydrocannabinol administration in male rhesus macaques infected with simian immunodeficiency virus: a systems biology analysis.Recreational amphetamine use and risk of HIV-related non-Hodgkin lymphoma.Histone modifications are associated with Δ9-tetrahydrocannabinol-mediated alterations in antigen-specific T cell responsesEffect of Delta-9-tetrahydrocannabinol on mouse resistance to systemic Candida albicans infection.Differential induction of gamma interferon in Legionella pneumophila-infected macrophages from BALB/c and A/J mice.Use of cannabinoids as a novel therapeutic modality against autoimmune hepatitis.Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and diseaseRecreational drug use and risk of Kaposi's sarcoma in HIV- and HHV-8-coinfected homosexual men.Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites.Cannabinoid receptor activation leads to massive mobilization of myeloid-derived suppressor cells with potent immunosuppressive propertiesMicrobial infections, immunomodulation, and drugs of abuse.Cannabinoids and neuroinflammation.Targeting cannabinoid receptors as a novel approach in the treatment of graft-versus-host disease: evidence from an experimental murine model.The cannabinoid system and immune modulation.Perinatal exposure to Δ9-tetrahydrocannabinol triggers profound defects in T cell differentiation and function in fetal and postnatal stages of life, including decreased responsiveness to HIV antigens.Anandamide, Acting via CB2 Receptors, Alleviates LPS-Induced Neuroinflammation in Rat Primary Microglial Cultures.Role of Toll-like receptor 9 in Legionella pneumophila-induced interleukin-12 p40 production in bone marrow-derived dendritic cells and macrophages from permissive and nonpermissive mice.Exposure to Δ9-Tetrahydrocannabinol Impairs the Differentiation of Human Monocyte-derived Dendritic Cells and their Capacity for T cell Activation.Effects of Cannabinoids on T-cell Function and Resistance to Infection.Cannabinoid receptor 2-mediated attenuation of CXCR4-tropic HIV infection in primary CD4+ T cellsCannabinoid 2 (CB2) receptor involvement in the down-regulation but not up-regulation of serum IgE levels in immunized mice.Magnitude of stimulation dictates the cannabinoid-mediated differential T cell response to HIVgp120.Effects of pro-inflammatory cytokines on cannabinoid CB1 and CB2 receptors in immune cellsSignaling through cannabinoid receptor 2 suppresses murine dendritic cell migration by inhibiting matrix metalloproteinase 9 expression.The peripheral cannabinoid receptor knockout mice: an update.Δ9-tetrahydrocannabinol impairs the inflammatory response to influenza infection: role of antigen-presenting cells and the cannabinoid receptors 1 and 2.Differential expression of intracellular and extracellular CB(2) cannabinoid receptor protein by human peripheral blood leukocytes.On the pharmacological properties of Delta9-tetrahydrocannabinol (THC).Cannabinoid-induced immune suppression and modulation of antigen-presenting cells.Drugs of abuse, immune modulation, and AIDS.Immunoactive effects of cannabinoids: considerations for the therapeutic use of cannabinoid receptor agonists and antagonists.Do cannabinoids have a therapeutic role in transplantation?
P2860
Q24647850-7EE3004E-C2AA-47A1-993C-EB5ACB4AC5E2Q24648473-D01A1A77-948C-4FDE-9D34-7106DD99DEE2Q24814542-FBE365E8-8DD3-47EC-9702-CD63B1EA0D4DQ27024102-5CCE1465-0C78-4E70-9415-60E0BCA180E9Q28077898-9473BEBD-D78D-489C-B260-A7C9D1F0F49EQ30357558-62630935-C0D2-41EB-B7E8-FECC500824E4Q33687100-2B5A25BF-E223-4AF2-B0EE-4B1F0C2DAE29Q33688381-BA4E78E1-8001-404A-A8DC-D628303DD4F1Q33713868-BBAF0F14-5E50-4375-B859-BA9F56F57043Q33822624-D457D0D2-94AC-4DEE-9F74-00B95C354718Q33846410-BA15B9CC-6527-431C-9AC6-63D64F3CE316Q33946093-C46345CF-7DC2-4667-B162-648BEECDCE92Q34007583-982EF922-55F7-4A8D-BB74-65A62CCE4C67Q34069579-6D0FF2F6-DEB3-4C9A-B37D-55AEEC452BD6Q34188446-C0FDB6ED-6D26-4765-A58B-CF0EA7B886F2Q34309880-840F0B80-4C46-4000-9580-F67FE8EA1845Q34471868-27BC1896-FDCA-4BCC-94D2-A2B33C6ADE30Q34789214-9D7E3526-2780-438F-9FE7-AF2135F4B263Q34926928-E0D4FAF4-32DE-4257-9BA9-D2D3F40C959CQ35046205-F5823ED0-658A-4164-8FAA-DF29981A35F2Q35188151-AC3F84EF-F221-48E7-B4E8-B135BA882167Q35213813-7474B214-0FC4-4022-9F03-54E50C9168C5Q35429696-C5867589-6608-48FD-8E04-8D742B31CDF3Q35674014-FE7CC7D2-4F55-48FB-B176-8908BD2F6FECQ35689020-E4B71996-A42C-4F4D-8DE5-947A6446D3FDQ35752103-45065735-E280-414F-9E56-6133CF3E8DFEQ35752185-729B1643-7777-48B6-B0AA-0CDC972BB260Q35842577-5D942549-6839-48E9-8528-DA298FE17BB2Q36166294-168DC5FB-6AB8-4578-82E4-02C81D4BA276Q36332726-3C320346-0B98-4A22-A003-69F693D6EEC4Q36347677-05911843-C83C-4D2A-8265-7F7A6003F7F1Q36370835-B35E3105-E38A-49B4-A184-0C7B7268FE07Q36416347-4C3215FE-C42D-4F2F-BC59-F1F075AFA8AFQ36551447-5D517015-2714-4D41-B935-AE2F011DCE03Q36653071-2C4F6C6D-3B93-418B-B9B2-5604F34CAC1BQ36916114-CC4E6268-5782-406F-A30F-7F58DFE0E757Q37015392-C6380298-394A-4B89-B6EC-0067E6E9F8E2Q37015427-EC6FEF4A-A4A5-4091-9420-72287E1A1850Q37244823-1D4DFF14-13C8-4CA9-9834-1BBD52499744Q37768965-784558AE-04D6-47C7-8692-20B9511C8ED2
P2860
Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Delta 9-tetrahydrocannabinol t ...... ionella pneumophila infection.
@ast
Delta 9-tetrahydrocannabinol t ...... ionella pneumophila infection.
@en
type
label
Delta 9-tetrahydrocannabinol t ...... ionella pneumophila infection.
@ast
Delta 9-tetrahydrocannabinol t ...... ionella pneumophila infection.
@en
prefLabel
Delta 9-tetrahydrocannabinol t ...... ionella pneumophila infection.
@ast
Delta 9-tetrahydrocannabinol t ...... ionella pneumophila infection.
@en
P2093
P1476
Delta 9-tetrahydrocannabinol t ...... ionella pneumophila infection.
@en
P2093
P304
P356
10.4049/JIMMUNOL.164.12.6461
P407
P577
2000-06-01T00:00:00Z